Will leverage Innovent's therapeutic antibody portfolio and discovery capability against undisclosed oncology targets in combination with Bolt's ISAC technology
Clinical leaders discuss bringing together disparate processes and systems for improved collaboration and more efficient trial execution at Veeva R&D Summit
Online ExclusivesJim Reilly, vice president of clinical strategy at Veeva Systems10.18.19